'For quarter ending June 2024, consolidated Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 5.96% to Rs 12652.75 crore compared to quarter ended June 2023.  Operating profit margin has jumped from 27.90% to 28.51%, leading to 8.28% rise in operating profit to Rs 3,607.62 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.81% to 12.42%.   Purchase of finished goods cost rose from 5.80% to 7.96%.   Employee cost decreased from 20.50% to 19.59%.   Other expenses rose from 29.44% to 31.24%.   

Other income rose 160.49% to Rs 532.55 crore.  PBIDT rose 17.08% to Rs 4140.17 crore.  Provision for interest fell 23.91% to Rs 61.54 crore.  

PBDT rose 18.04% to Rs 4078.63 crore.  Provision for depreciation rose 0.58% to Rs 655.13 crore.  

Profit before tax grew 22.09% to Rs 3,423.50 c...

• 

  (13-Jan-2025)

  Avenue Supermarts

  Revenue up 17.7% YoY, Net profit up 4.8% YoY in Q3FY2025

• 

  (12-Jan-2025)

  Just Dial

  Sales up 8%, net up 43%

• 

  (10-Jan-2025)

  PCBL

  Lower profits

• 

  (10-Jan-2025)

  Tata Consultancy Services

  Revenue up 5.6% YoY to Rs 63973 crore in Q3FY2025